Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Blood (2024) 144 (19): 1993–2001.

https://doi.org/10.1182/blood.2024024657

Published: 2024

Includes: Supplemental data

Journal Articles

Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Blood (2023) 142 (Supplement 1): 4641.

https://doi.org/10.1182/blood-2023-181595

Published: 2023

Journal Articles

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Blood (2023) 142 (Supplement 1): 865.

https://doi.org/10.1182/blood-2023-172583

Published: 2023

Journal Articles

Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1 , GATA2 and DDX41

Anna L. Brown, Claire Homan, Michael W. Drazer, Kai Yu, David Lawrence, Jinghua Feng, Luis Arriola-Martinez, Matthew Pozsgai, Kelsey McNeely, Thuong Ha, Parvathy Venugopal, Peer Arts, Sarah King-Smith, Jesse JC Cheah, Mark Armstrong, Csaba Bödör, Paul Wang, Alan B. Cantor, Mario Cazzola, Erin Degelman, Courtney D. DiNardo, Nicolas Duployez, Remi Favier, Stefan Fröhling, Ana Rio-Machin, Jeffery M. Klco, Alwin Krämer, Mineo Kurokawa, Joanne Lee, Luca Malcovati, Neil V Morgan, Georges Natsoulis, Carolyn Owen, Keyur P. Patel, Claude Preudhomme, Hana Raslova, Hugh Young Rienhoff, Jr., Tim Ripperger, Rachael Schulte, Kiran Tawana, Elvira Deolinda Rodrigues Pereira Velloso, Benedict Yan, Raman Sood, Amy Hsu, Steven M. Holland, Kerry Phillips, Nicola Poplawski, Milena Babic, Erika M Kwon Kim, Andrew H. Wei, Cecily Forsyth, Helen Mar Fan, Ian D Lewis, Julian Cooney, Rachel Susman, Lucy C Fox, Piers Blombery, Deepak Singhal, Devendra Hiwase, Andreas W Schreiber, Christopher N Hahn, Hamish S Scott, Paul P. Liu, Lucy A. Godley

Blood (2022) 140 (Supplement 1): 4030–4033.

https://doi.org/10.1182/blood-2022-167600

Published: 2022

Journal Articles

Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

Blood (2022) 140 (Supplement 1): 192–194.

https://doi.org/10.1182/blood-2022-157244

Published: 2022

Journal Articles

Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Blood (2021) 138 (Supplement 1): 4757.

https://doi.org/10.1182/blood-2021-147622

Published: 2021

Journal Articles

Totality of Scientific Evidence in the Development of ABP 798, a Biosimilar to Rituximab

Dietger Niederwieser, MD PhD, Caroline Hamm, MD, Patrick Cobb, MD, Theingi Thway, PhD, Cecily Forsyth, FRACP, FRCPA, MBBS, Alessandra Tucci, MD, Vincent Delwail, Roman Hajek, MD PhD, Vladimir Hanes, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142723

Published: 2020

Journal Articles

Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-136145

Published: 2020

Journal Articles

Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Anna L. Brown, PhD BSc, Mark Armstrong, MSc, David Lawrence, Paul Wang, Peer Arts, PhD, Nicolas Duployez, PharmD, PhD, Jane Churpek, MD, Kiran Tawana, MD, Erin Degelman, MSc, BSc, Georges Natsoulis, PhD, Monica L. Guzman, PhD, Mrinal M. Patnaik, MD MBBS, Akiko Shimamura, MD PhD, Alan B. Cantor, MD PhD, Tim Ripperger, MD PhD, Brigitte Schlegelberger, MD PhD, Doris Steinemann, PhD, Courtney D. DiNardo, MD MSc, Cristina Mecucci, MD PhD, Elvira DRP Velloso, MD PhD, Fabio PS Santos, MD, Marcela CA Silva, Uma Borate, MD, Shannon K. McWeeney, PhD, Grzegorz Nalepa, MD PhD, Susanne Ragg, MD PhD, Erika Mijin Kwon, PhD, Anupriya Agarwal, PhD, Stephen Langabeer, PhD, Jeffery M. Klco, MD PhD, Jun J. Yang, PhD, Cecily Forsyth, FRACP, FRCPA, MBBS, Sally Mapp, MD PhD, Helen Mar Fan, MD, Lesley Rawlings, PhD, Rachel Susman, Sue Morgan, FRACP, FRCPA, MBBS, Andrew H Wei, MBBS,PhD, Inderjeet Dokal, MD, Tom Vulliamy, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Deepak Singhal, MBBS, MD FRACP, FRCPA, Susan Branford, PhD, Elli Papaemmanuil, PhD, Jean Soulier, MDPhD, Stefan Fröhling, MD, Alwin Kramer, MD, Guy Sauvageau, MD PhD, Neil Morgan, Carolyn Owen, Csaba Bödör, PhD, Jude Fitzgibbon, Hugh Y. Rienhoff, Jr., MD, Mineo Kurokawa, MD PhD, Lucy Godley, MD PhD, Claude Preudhomme, Paul P Liu, MD PhD, Nicola Poplawski, MD, Christopher N. Hahn, PhD, Hamish S. Scott, PhD

Blood (2018) 132 (Supplement 1): 5241.

https://doi.org/10.1182/blood-2018-99-118017

Published: 2018

Journal Articles

Deficiencies in Immunoglobulin Classes and Immunoglobulin G Subclasses Are Associated with Shorter Treatment Free Survival and Overall Survival in CLL

Kyle R Crassini, MBBS,BE,BSc, Eva Zhang, MBBS, Shalini Balendran, MBBS, Jane Freeman, BA,FRACP,FRCPA,MBBS,MPhil,MSc, Oliver Giles Best, PhDBSc, Cecily Forsyth, FRACP, FRCPA, MBBS, Naomi Mackinlay, Ping Han, MDPhD, William S. Stevenson, MBBS,PhD, Stephen Mulligan, PhDFRACP,FRCPA,MBBS

Blood (2017) 130 (Supplement 1): 5321.

https://doi.org/10.1182/blood.V130.Suppl_1.5321.5321

Published: 2017

Journal Articles

Hydroxycarbamide Plus Aspirin Vs Aspirin Alone in Intermediate Risk Essential Thrombocythemia: Results of the PT-1 International, Prospective, Randomized Clinical Trial

Anna L. Godfrey, BMBCh, PhD MRCP, FRCPath, Peter J Campbell, MD PhD, Cathy MacLean, BSc, MSc, MBA, Georgina Buck, BSc, MSc, Clare L. East, BSc, Julia Cook, BSc, Julie Temple, BSc, Bridget S. Wilkins, MD FRCPath, Keith Wheatley, DPhil, Jyoti Nangalia, MBBChir, MA, MRCP, FRCPath, PhD, Jacob Grinfeld, MBChB, BSc, MRCP, FRCPath, Mary Frances Frances McMullin, MB,Bch BAO, MD FRCPath, Cecily Forsyth, MB BS, Jean-Jacques Kiladjian, MD PhD, Anthony R. Green, FRCP, FRCPath, FMed Sci, Claire N. Harrison, BMBCh, DM, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 319.

https://doi.org/10.1182/blood.V130.Suppl_1.319.319

Published: 2017

Journal Articles

Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations

Anna L Brown, PhD, Christopher N Hahn, PhD, Catherine Carmichael, Ella Wilkins, Milena Babic, BMPharBio (Hons), Chan-Eng Chong, PhD, Xiao-Chun Li, Joelle Michaud, Ping Cannon, Nicola Poplawski, MBChB, DipPaed, FRACP, MD, Meryl Altree, Kerry Phillips, Louise Jaensch, Miriam Fine, Andreas W Schreiber, PhD, Jinghua Feng, PhD, Lesley Rawlings, PhD, Cassandra Vakulin, Carolyn Butcher, Richard D'Andrea, PhD, Ian D Lewis, MBBS, PhD FRACP, FRCPA, Nigel Patton, Cecily Forsyth, MBBS, FRACP, FRCPA, Sally Mapp, PhD MD, Helen Mar Fan, Rachel Susman, Sue Morgan, FRACP, FRCPA, MBBS, Julian Cooney, MD, Mark S Currie, MD, Uday R. Popat, MD, Kenneth Bradstock, MBBS, PhD, April D. Sorrell, MD, Carolyn J. Owen, MD MDes(UK), FRCPC, Marshall S Horwitz, MD PhD, Devendra Hiwase, MBBS, FRACP, FRCPA, MD PhD, Alwin Krämer, MD, Stefan Fröhling, MD, Lucy A Godley, MD PhD, Jane E Churpek, MD, Hamish S Scott, BSc, PhD FFSc (RCPA), FAHMS

Blood (2016) 128 (22): 1212.

https://doi.org/10.1182/blood.V128.22.1212.1212

Published: 2016

Journal Articles

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Blood (2016) 128 (22): 939.

https://doi.org/10.1182/blood.V128.22.939.939

Published: 2016

Journal Articles

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Suneet Sandhu, MBBS, MPH, FRACP, FRCPA, Devinder Gill, MB FRCPath FRACP FRCPA, Paul David Turner, MBBS, FRACP, FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Leanne Berkahn, MD, David R Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily Forsyth, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Rosemary Harrup, MBBS, FRACP, FRCPA, Giles Best, BSc, PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone Jean Kuss, PhD MBBS, FRCPA, FRACP, Stephen Mulligan, MBBS, PhD FRACP, FRCPA

Blood (2015) 126 (23): 5295.

https://doi.org/10.1182/blood.V126.23.5295.5295

Published: 2015

Journal Articles

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

Peter J. Campbell, Cathy MacLean, Philip A. Beer, Georgina Buck, Keith Wheatley, Jean-Jacques Kiladjian, Cecily Forsyth, Claire N. Harrison, Anthony R. Green

Blood (2012) 120 (7): 1409–1411.

https://doi.org/10.1182/blood-2012-04-424911

Published: 2012

Journal Articles

Result of FDG PET-CT Imaging After Immunochemotherapy Induction Is a Powerful and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: An Analysis From the PRIMA Study

Judith Trotman, MBChB, FRACP, FRCPA, Marion Fournier, Thierry Lamy, MD, PhD, Jane A Estell, MBBS, FRCPA, FRACP, Anne Sonet, MD, Andrea Janikova, MD, PhD, Herve Tilly, Didier Decaudin, Jean Gabarre, MD, John F Seymour, MD, FRACP, Etienne Garin, Cecily Forsyth, Michael Fulham, MBBS, FRACP, Thierry Vander Borght, MD, PhD, Ofer Shpilberg, MD, MPH, Gilles Salles

Blood (2010) 116 (21): 855.

https://doi.org/10.1182/blood.V116.21.855.855

Published: 2010

Journal Articles

FDG PET-CT in Primary Staging and Management of Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL): Experience in 465 Consecutive Patients.

Michael J. Fulham, MB, BS, Melinda Gibson, BA, Judith Trotman, MB.BS, Cecily Forsyth, MB.BS, Ilona Cunningham, MB.BS, Armin Mohamed, MB.BS, Graham Young, MB.BS

Blood (2006) 108 (11): 2398.

https://doi.org/10.1182/blood.V108.11.2398.2398

Published: 2006

NARROW

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1 , GATA2 and DDX41

Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Totality of Scientific Evidence in the Development of ABP 798, a Biosimilar to Rituximab

Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Deficiencies in Immunoglobulin Classes and Immunoglobulin G Subclasses Are Associated with Shorter Treatment Free Survival and Overall Survival in CLL

Hydroxycarbamide Plus Aspirin Vs Aspirin Alone in Intermediate Risk Essential Thrombocythemia: Results of the PT-1 International, Prospective, Randomized Clinical Trial

Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

Result of FDG PET-CT Imaging After Immunochemotherapy Induction Is a Powerful and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: An Analysis From the PRIMA Study

FDG PET-CT in Primary Staging and Management of Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL): Experience in 465 Consecutive Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only